AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35768113
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules daily for 8 weeks preoperatively
Trial: 34282985
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase (baseline ≥5 cerebral microbleeds)
Trial: 34343140
Drug: Rehabilitative therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitative therapies such as exercise, respiratory muscle training, assistive devices, and manual therapy and stretching
Trial: 35665947
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days amoxicillin 1 g + clarithromycin 500 mg + vonoprazan 20 mg twice per day
Trial: 35665947
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days amoxicillin 1 g + clarithromycin 500 mg + PPI (omeprazole or esomeprazole or rabeprazole) 20 mg twice/day
Trial: 32871029
Drug: HD-DXM monotherapy
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-DXM monotherapy
Trial: 32008730
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone 400 mg twice daily
Trial: 32471476
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment group
Trial: 34235780
Drug: Air mixed
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air mixed with emissions from cooking (PM2.5: 96.1 μg/m3)
Trial: 34235780
Drug: Air mixed
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air mixed with emissions from candles (PM2.5: 89.8 μg/m3)
Trial: 34235780
Drug: Clean filtered
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean filtered air (PM2.5: 5.8 μg/m3)
Trial: 32965030
Drug: Topical Calendula
RxNorm normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Calendula officinalis
Trial: 32965030
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (Sorbolene: 10% glycerine in cetomacragol cream)
Trial: 35870478
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic stewardship measures (Control)
Trial: 33249467
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg (or dose-reduced 30 mg)
Trial: 36193812
Drug: 250 or
RxNorm normalized name: Urso-250 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 or 600 mL m‐2 of cow's milk
Trial: 36172955
Drug: Dietitian-led intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietitian-led intervention with motivational interviewing during weekly calls
Trial: 33465772
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year
Trial: 33465772
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of anti-VEGF therapy after 1 year of treatment
Trial: 34214881
Drug: Alcohol drinkers
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol drinkers (>0 g/day of alcohol intake)
Trial: 34214881
Drug: Non-drinkers (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drinkers (0 g/day of alcohol intake)
Trial: 33104258
Drug: Sulfotanshinone sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfotanshinone sodium injection combined with tirofiban (n = 99)
Trial: 32828785
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplements
Trial: 32828785
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium supplements
Trial: 32196110
Drug: Intradiscal gelified
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal gelified ethanol injection (Discogel)
Trial: 32196110
Drug: Intradiscal combination
RxNorm normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal combination of pulsed radiofrequency and gelified ethanol injection (PRF+Discogel)
Trial: 36279690
Drug: Intravaginal laser
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal laser therapy (2 courses within 1 month)
Trial: 36279690
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid suppositories (3 times/week for 3 months)
Trial: 35379314
Drug: Active daily
RxNorm normalized name: HOMOSALATE 3 mL in 100 mL / OCTINOXATE 8 mL in 100 mL / OXYBENZONE 2 mL in 100 mL TOPICAL LIQUID [GLAMTOX ACTIVE DAILY MOISTURIZING SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active daily use of Alpha-Stim AID for 8 weeks
Trial: 33352495
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug of Coccinia grandis (500 mg once daily for three months)
Trial: 33352495
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for three months)
Trial: 32812025
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg), Daclatasvir (60 mg), Ribavirin (1200 mg)
Trial: 38451525
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor monotherapy after 3 months of DAPT
Trial: 36202933
Drug: Oral eplerenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eplerenone
Trial: 36202933
Drug: Half-dose PDT
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose PDT (crossover treatment)
Trial: 33986477
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha (Darbe) 10 μg/kg IV
Trial: 33432167
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BNT) injections
Trial: 32986235
Drug: Drug-coated balloons
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-coated balloons
Trial: 34523382
Drug: Nebulised dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised dexmedetomidine 2 μg/kg (group D)
Trial: 34523382
Drug: Nebulised ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised ketamine 2 mg/kg (group K)
Trial: 32866050
Drug: 25% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish without fTCP
Trial: 32866050
Drug: 25% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish with functionalized tricalcium phosphate (fTCP)
Trial: 33296830
Drug: nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel plus gemcitabine (nab-P/G)
Trial: 33232476
Drug: Pacritinib 100
RxNorm normalized name: pacritinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 100 mg once per day
Trial: 33232476
Drug: Pacritinib 100
RxNorm normalized name: pacritinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 100 mg twice per day
Trial: 33232476
Drug: Pacritinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 200 mg twice per day
Trial: 34698889
Drug: Atorvastatin (37.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (37.9% of participants)
Trial: 34698889
Drug: High-potency statins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency statins (atorvastatin and rosuvastatin)
Trial: 34929410
Drug: Seven-day course
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-day course of antibiotics
Trial: 34929410
Drug: Fourteen-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourteen-day course of antibiotics
Trial: 36153529
Drug: Ensuring the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensuring the availability of influenza vaccine supply
Trial: 36153529
Drug: Developing influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developing influenza vaccine awareness
Trial: 36153529
Drug: Both ensuring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ensuring influenza vaccine supply and developing influenza vaccine awareness
Trial: 35724670
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg plus FDCSL (400/90 mg)
Trial: 34821105
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tangeretin orally for 4 weeks
Trial: 32951708
Drug: Eugenol nanoemulsion
RxNorm normalized name: Eugenol
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eugenol nanoemulsion gel 4%
Trial: 35964610
Drug: Mepolizumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (40 mg for 6–11 years; 100 mg for 12–17 years)
Trial: 35768897
Drug: Wrist Position
RxNorm normalized name: histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wrist Position Sense Test (WPST) treatment group (n=10)
Trial: 32952830
Drug: 400μg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400μg sublingual Misoprostol
Trial: 36384662
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg subcutaneous every 2 weeks)
Trial: 33742240
Drug: Dexamethasone premedication
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone premedication (8 mg/twice daily for 3 days) followed by tapering dexamethasone (4 mg/daily for 2 days followed by 2 mg/daily for 2 days)
Trial: 33742240
Drug: Dexamethasone premedication
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone premedication (8 mg/twice daily for 3 days)
Trial: 32367340
Drug: ezetimibe/rosuvastatin 10/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/rosuvastatin 10/5 mg
Trial: 35729758
Drug: Ketogenic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic diet (KD) (∼25 g CHO/d)
Trial: 35729758
Drug: Carbohydrate diet
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate diet (CHO) (∼285 g CHO/d)
Trial: 34112100
Drug: Water-based intimate
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based intimate lubricant gel
Trial: 36249225
Drug: Thermometer patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermometer patch (Tucky thermometer) for 3 weeks
Trial: 35019120
Drug: Physiologic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic Solution (PS) group
Trial: 33321462
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PRESSING panel and response dynamics
Trial: 33074769
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release (SR) tablets of isradipine composed of 15.0% (wt/wt) HPMC
Trial: 33074769
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) tablets of isradipine
Trial: 33402409
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg daily or 30 mg daily if patients had dose-reduction criteria)
Trial: 33402409
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) using aspirin (100 mg daily) plus clopidogrel (75 mg daily) for 6 months
Trial: 35905861
Drug: Control (listing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (listing daily activities)
Trial: 34090987
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (SET) 3× weekly for 6 months
Trial: 34090987
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1× weekly health lectures)
Trial: 34236915
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic therapy with clopidogrel
Trial: 34236915
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic therapy with potent P2Y12 inhibitors (ticagrelor or prasugrel)
Trial: 32762229
Drug: Fractional ultrapulsed
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional ultrapulsed CO2 laser (group L, n=30)
Trial: 34971723
Drug: Midazolam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (30 μg/kg)
Trial: 33068444
Drug: Secukinumab low
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab low dose (LD: 75/75/150 mg)
Trial: 33068444
Drug: Secukinumab high
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab high dose (HD: 75/150/300 mg)
Trial: 33068444
Drug: Secukinumab low
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab low dose (LD)
Trial: 33068444
Drug: Secukinumab high
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab high dose (HD)
Trial: 33068444
Drug: Etanercept (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.8 mg/kg up to a max of 50 mg)
Trial: 32243575
Drug: Oral-B iO
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B iO electric toothbrush
Trial: 33372745
Drug: Enoxaparin adjusted
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin adjusted to anti‐Xa level of 0.2‐0.5 international units/mL started at less than 24 hours after insertion of central venous catheter
Trial: 36268462
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOACs) - apixaban, edoxaban, rivaroxaban
Trial: 36453014
Drug: G-Rup® syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Rup® syrup (30 ml twice daily for 12 weeks)
Trial: 34842573
Drug: Selenase (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenase (intravenous selenium) for 5 days
Trial: 33891831
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, n = 713
Trial: 33891831
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, n = 751
Trial: 33592868
Drug: A+HA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A+HA (20 mL daily for 8 weeks)
Trial: 33592868
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL daily for 8 weeks)
Trial: 36306168
Drug: AbobotulinumtoxinA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (2 U/kg for cycle 1 only, 8 U/kg and 16 U/kg) followed by a tailored home exercises therapy programme
Trial: 36306168
Drug: AbobotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA treatment cycles
Trial: 35007482
Drug: Therapist-administered hypnosis
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-administered hypnosis (Group A) for 8 weeks
Trial: 32312261
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract 500 mg
Trial: 36181471
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg (or maximum-tolerated dose)
Trial: 33531563
Drug: Spaced-learning (2-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced-learning (2-h weekly sessions over 4 weeks)
Trial: 33843297
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity on prescription (n=72)
Trial: 34386824
Drug: Open surgical
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgical exposure with orthodontic treatment
Trial: 34386824
Drug: Closed surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed surgical exposure with orthodontic treatment
Trial: 32507132
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) treatment, 12 min/session, three sessions/week for four weeks.
Trial: 32507132
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group), blinded to participants, for two weeks.
Trial: 32331031
Drug: Biofeedback and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback and analgesics
Trial: 32331031
Drug: Analgesics alone
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics alone
Trial: 35260450
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and angiotensin receptor blockers
Trial: 35993376
Drug: Control (prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (prescription drug misuse posts)
Trial: 34735908
Drug: RPGE (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPGE (375 mg, 2 tablets, 2 times/day)
Trial: 32682074
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI (160/7.2/4.8 μg per actuation) with a 10-second breath-hold
Trial: 32682074
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI (160/7.2/4.8 μg per actuation) with a 3-second breath-hold
Trial: 32682074
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI (160/7.2/4.8 μg per actuation)
Trial: 34497027
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (without currents delivered)
Trial: 34999268
Drug: Craving during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craving during treatment
Trial: 35473742
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention (informational and testimonial video about opioid tapering + two text messages per day for 28 days)
Trial: 34953185
Drug: Ketoprofen lysine
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen lysine salt solution
Trial: 34953185
Drug: Native vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native vitamin D prescriptions
Trial: 33307151
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment schedules
Trial: 35639365
Drug: Coffee (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (2 cups per day, total amount 160 mg caffeine)
Trial: 35639365
Drug: Green Tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Tea (3 cups per day, total amount 252 mg catechin and 96 mg caffeine)
Trial: 33596746
Drug: Lactulose 15
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 15 mL once daily
Trial: 33596746
Drug: Sennosides two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sennosides two tablets daily
Trial: 32600454
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (Nebido®)